sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Lasmiditan

Medicine

Lasmiditan

REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

Who should not take it

None.

Storing it

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

2 dosage and administration

The recommended dose of REYVOW is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose should be taken in 24 hours, and REYVOW should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery.

A second dose of REYVOW has not been shown to be effective for the same migraine attack.

The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.

REYVOW may be taken with or without food.

Administer tablets whole; do not split, crush, or chew.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Lasmiditan; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/lasmiditan

APA 7th

sofidex. (2026, August 3). Lasmiditan. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/lasmiditan

AMA 11th

Lasmiditan. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/lasmiditan

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.